Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report) and Roche ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in ...

The latest analyst coverage could presage a bad day for Protagonist Therapeutics, Inc. (NASDAQ:PTGX), with the analysts making across-the-board cuts to their statutory estimates that might leave ...